Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

Simon DK, Simuni T, Elm J, Clark-Matott J, Graebner AK, Baker L, Dunlop SR, Emborg M, Kamp C, Morgan JC, Ross GW, Sharma S, Ravina B; NINDS NET-PD Investigators.

J Parkinsons Dis. 2015;5(4):731-6. doi: 10.3233/JPD-150666.

PMID:
26444095
2.

Inhibition of Thrombopoietin/Mpl Signaling in Adult Hematopoiesis Identifies New Candidates for Hematopoietic Stem Cell Maintenance.

Kohlscheen S, Wintterle S, Schwarzer A, Kamp C, Brugman MH, Breuer DC, Büsche G, Baum C, Modlich U.

PLoS One. 2015 Jul 6;10(7):e0131866. doi: 10.1371/journal.pone.0131866. eCollection 2015.

3.

Cancer, Warts, or Asymptomatic Infections: Clinical Presentation Matches Codon Usage Preferences in Human Papillomaviruses.

Félez-Sánchez M, Trösemeier JH, Bedhomme S, González-Bravo MI, Kamp C, Bravo IG.

Genome Biol Evol. 2015 Jul 1;7(8):2117-35. doi: 10.1093/gbe/evv129.

4.

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators.

Lancet Neurol. 2015 Aug;14(8):795-803. doi: 10.1016/S1474-4422(15)00144-1. Epub 2015 Jun 23. Erratum in: Lancet Neurol. 2015 Oct; 14(10):979.

5.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM.

JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.

6.

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators.

J Parkinsons Dis. 2014;4(4):629-38. doi: 10.3233/JPD-140383.

PMID:
25062961
7.

Sexual risk behaviour and donor deferral in Europe.

Offergeld R, Kamp C, Heiden M, Norda R, Behr-Gross ME.

Vox Sang. 2014 Nov;107(4):420-7. doi: 10.1111/vox.12179. Epub 2014 Jul 17.

PMID:
25040600
8.

Does the motor system need intermittent control?

Loram ID, van de Kamp C, Lakie M, Gollee H, Gawthrop PJ.

Exerc Sport Sci Rev. 2014 Jul;42(3):117-25. doi: 10.1249/JES.0000000000000018. Review.

PMID:
24819544
9.

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators.

JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391.

10.

Exercise reduces the symptoms of attention-deficit/hyperactivity disorder and improves social behaviour, motor skills, strength and neuropsychological parameters.

Kamp CF, Sperlich B, Holmberg HC.

Acta Paediatr. 2014 Jul;103(7):709-14. doi: 10.1111/apa.12628. Epub 2014 Apr 29. Review.

PMID:
24612421
11.

Epidemic spread on weighted networks.

Kamp C, Moslonka-Lefebvre M, Alizon S.

PLoS Comput Biol. 2013;9(12):e1003352. doi: 10.1371/journal.pcbi.1003352. Epub 2013 Dec 12.

12.

Interfacing sensory input with motor output: does the control architecture converge to a serial process along a single channel?

van de Kamp C, Gawthrop PJ, Gollee H, Lakie M, Loram ID.

Front Comput Neurosci. 2013 May 9;7:55. doi: 10.3389/fncom.2013.00055. eCollection 2013.

13.

Caffeine consumption and risk of dyskinesia in CALM-PD.

Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA; Parkinson Study Group.

Mov Disord. 2013 Mar;28(3):380-3. doi: 10.1002/mds.25319. Epub 2013 Jan 21.

14.

Refractoriness in sustained visuo-manual control: is the refractory duration intrinsic or does it depend on external system properties?

van de Kamp C, Gawthrop PJ, Gollee H, Loram ID.

PLoS Comput Biol. 2013;9(1):e1002843. doi: 10.1371/journal.pcbi.1002843. Epub 2013 Jan 3.

15.

Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.

Münk C, Jensen BE, Zielonka J, Häussinger D, Kamp C.

Viruses. 2012 Nov 14;4(11):3132-61. doi: 10.3390/v4113132. Review.

17.

Identification of intermittent control in man and machine.

Loram ID, van de Kamp C, Gollee H, Gawthrop PJ.

J R Soc Interface. 2012 Sep 7;9(74):2070-84. doi: 10.1098/rsif.2012.0142. Epub 2012 Apr 4.

18.

A common first-order time-to-contact based control of hand-closure initiation in catching and grasping.

van de Kamp C, Bongers RM, Zaal FT.

Hum Mov Sci. 2012 Jun;31(3):529-40. doi: 10.1016/j.humov.2011.06.007. Epub 2011 Aug 24.

PMID:
21868116
19.

Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION.

Dworkin RH, Turk DC, Katz NP, Rowbotham MC, Peirce-Sandner S, Cerny I, Clingman CS, Eloff BC, Farrar JT, Kamp C, McDermott MP, Rappaport BA, Sanhai WR.

Pain. 2011 Mar;152(3 Suppl):S107-15. doi: 10.1016/j.pain.2010.11.008. Epub 2010 Dec 9. Review. No abstract available.

PMID:
21145657
20.

Untangling the Interplay between Epidemic Spread and Transmission Network Dynamics.

Kamp C.

PLoS Comput Biol. 2010 Nov 18;6(11):e1000984. doi: 10.1371/journal.pcbi.1000984.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk